Alkem has launched Favipiravir under the brand name Alfluenza in the country for the management of mild to moderate cases of COVID-19.
Favipiravir is approved by the Drug Controller General of India (DCGI) for restricted emergency use. (IE)Alkem Laboratories on Wednesday said it has launched Favipiravir under the brand name ‘Alfluenza’ in the country for the treatment of COVID-19. COVID-19 cases are increasing significantly globally and India too is affected with around 50,000 new cases being added on a daily basis, Alkem Laboratories said in a statement.
In this backdrop, the company has launched Favipiravir under the brand name Alfluenza in the country for the management of mild to moderate cases of COVID-19, it added. Favipiravir is approved by the Drug Controller General of India (DCGI) for restricted emergency use. Restricted use entails responsible medication where every patient must have signed informed consent before treatment initiation, Alkem said.
Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.
Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.
